modernretina22d
Positive 2-year safety and efficacy update for Phase 1/2 OCU400 for the treatment of RP
OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes. Ocugen, Inc.
BMJ4mon
Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity
Results: Among 167 patients, mean age was 48 (10) years, with median Expanded Disability Status Scale (EDSS) 2.0 (range 1.0–7.5), and median binocular Snellen acuity equivalent (ETDRS charts) 20/16 ...
ophthalmologytimes20d
Ocugen announces positive 2-year safety and efficacy update of Phase 1/2 OCU400 for treatment of retinitis pigmentosa
OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes. Ocugen, Inc.